Assertio Completes Merger with Zyla Life Sciences

Assertio Holdings, Inc., the successor issuer to Assertio Therapeutics, Inc., (“Assertio” ) (NASDAQ: ASRT) announced the closing of the merger with Zyla Life Sciences. The combined company (the “Company”) will operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products. The Company now has a differentiated portfolio of non-steroidal anti-inflammatory drugs (NSAIDs) commonly used by neurologists, orthopedic surgeons, internists, women’s health providers, podiatrists, pain care specialists and urologists. All eight products are branded, FDA-approved products and will be managed by the Company’s newly formed and highly experienced commercial team.

Read the full article: Assertio Completes Merger with Zyla Life Sciences //


Scroll to Top